nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—ALB—Acitretin—psoriasis	0.165	0.265	CbGbCtD
Bismuth Subsalicylate—PTGS2—Triamcinolone—psoriasis	0.122	0.196	CbGbCtD
Bismuth Subsalicylate—PTGS2—Betamethasone—psoriasis	0.105	0.168	CbGbCtD
Bismuth Subsalicylate—ALB—Mycophenolate mofetil—psoriasis	0.0772	0.124	CbGbCtD
Bismuth Subsalicylate—ALB—Prednisone—psoriasis	0.0618	0.099	CbGbCtD
Bismuth Subsalicylate—PTGS2—Dexamethasone—psoriasis	0.0611	0.098	CbGbCtD
Bismuth Subsalicylate—ALB—Methotrexate—psoriasis	0.031	0.0497	CbGbCtD
Bismuth Subsalicylate—TF—vertebral column—psoriasis	0.0241	0.409	CbGeAlD
Bismuth Subsalicylate—PTGS2—skeletal joint—psoriasis	0.00859	0.146	CbGeAlD
Bismuth Subsalicylate—PTGS2—synovial membrane of synovial joint—psoriasis	0.00652	0.111	CbGeAlD
Bismuth Subsalicylate—TF—skin of body—psoriasis	0.00457	0.0778	CbGeAlD
Bismuth Subsalicylate—PTGS2—skin epidermis—psoriasis	0.00418	0.0711	CbGeAlD
Bismuth Subsalicylate—PTGS1—endothelium—psoriasis	0.00318	0.054	CbGeAlD
Bismuth Subsalicylate—PTGS2—endothelium—psoriasis	0.00304	0.0516	CbGeAlD
Bismuth Subsalicylate—TF—Iron uptake and transport—CP—psoriasis	0.00209	0.0773	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—CP—psoriasis	0.00148	0.0549	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—skin of body—psoriasis	0.00136	0.0231	CbGeAlD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.00132	0.157	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—skin of body—psoriasis	0.0013	0.022	CbGeAlD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.00106	0.126	CbGdCrCtD
Bismuth Subsalicylate—TF—Hemostasis—SERPINB8—psoriasis	0.00104	0.0384	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—tendon—psoriasis	0.00103	0.0175	CbGeAlD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.00103	0.122	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—tendon—psoriasis	0.000987	0.0168	CbGeAlD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000836	0.0309	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000796	0.0948	CbGdCrCtD
Bismuth Subsalicylate—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000719	0.0266	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000676	0.025	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—IL13—psoriasis	0.00066	0.0244	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000638	0.076	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000638	0.076	CbGdCrCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.00063	0.0233	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.00062	0.0738	CbGdCrCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000531	0.0196	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000482	0.0574	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000482	0.0574	CbGdCrCtD
Bismuth Subsalicylate—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000475	0.00168	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Cyclosporine—psoriasis	0.000474	0.00168	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Methotrexate—psoriasis	0.000474	0.00168	CcSEcCtD
Bismuth Subsalicylate—Oedema—Hydroxyurea—psoriasis	0.000473	0.00168	CcSEcCtD
Bismuth Subsalicylate—Asthma—Triamcinolone—psoriasis	0.000471	0.00167	CcSEcCtD
Bismuth Subsalicylate—TF—Differentiation Pathway—VEGFA—psoriasis	0.000471	0.0174	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000471	0.0561	CbGdCrCtD
Bismuth Subsalicylate—Infection—Hydroxyurea—psoriasis	0.00047	0.00166	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Prednisolone—psoriasis	0.000466	0.00165	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Calcitriol—psoriasis	0.000463	0.00164	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Mycophenolate mofetil—psoriasis	0.000462	0.00164	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Hydrocortisone—psoriasis	0.000456	0.00162	CcSEcCtD
Bismuth Subsalicylate—Nausea—Methoxsalen—psoriasis	0.000451	0.0016	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Cyclosporine—psoriasis	0.000451	0.0016	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Hydroxyurea—psoriasis	0.000451	0.0016	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Methotrexate—psoriasis	0.000449	0.00159	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000441	0.0163	CbGpPWpGaD
Bismuth Subsalicylate—Hepatitis—Mycophenolate mofetil—psoriasis	0.00044	0.00156	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Prednisone—psoriasis	0.00044	0.00156	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Mycophenolate mofetil—psoriasis	0.000438	0.00155	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Calcitriol—psoriasis	0.00043	0.00153	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Triamcinolone—psoriasis	0.000429	0.00152	CcSEcCtD
Bismuth Subsalicylate—Rash—Calcitriol—psoriasis	0.000427	0.00151	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Calcitriol—psoriasis	0.000426	0.00151	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Acitretin—psoriasis	0.000426	0.00151	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Fluocinolone Acetonide—psoriasis	0.000425	0.00151	CcSEcCtD
Bismuth Subsalicylate—Headache—Calcitriol—psoriasis	0.000424	0.0015	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000421	0.0156	CbGpPWpGaD
Bismuth Subsalicylate—Tinnitus—Cyclosporine—psoriasis	0.00042	0.00149	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Hydroxyurea—psoriasis	0.00042	0.00149	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000418	0.0155	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Hydroxyurea—psoriasis	0.000416	0.00148	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—IL10—psoriasis	0.000413	0.0153	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Acitretin—psoriasis	0.000412	0.00146	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Hydroxyurea—psoriasis	0.000411	0.00146	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000411	0.00146	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Mycophenolate mofetil—psoriasis	0.00041	0.00145	CcSEcCtD
Bismuth Subsalicylate—Pain—Hydroxyurea—psoriasis	0.000404	0.00143	CcSEcCtD
Bismuth Subsalicylate—Constipation—Hydroxyurea—psoriasis	0.000404	0.00143	CcSEcCtD
Bismuth Subsalicylate—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000403	0.0149	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Calcitriol—psoriasis	0.000402	0.00143	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Mycophenolic acid—psoriasis	0.000399	0.00142	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Hydrocortisone—psoriasis	0.000399	0.00141	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Acitretin—psoriasis	0.000398	0.00141	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Fluocinolone Acetonide—psoriasis	0.000397	0.00141	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Triamcinolone—psoriasis	0.000396	0.00141	CcSEcCtD
Bismuth Subsalicylate—Oedema—Mycophenolic acid—psoriasis	0.000396	0.0014	CcSEcCtD
Bismuth Subsalicylate—Infection—Mycophenolic acid—psoriasis	0.000393	0.00139	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Hydroxyurea—psoriasis	0.00039	0.00138	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Dexamethasone—psoriasis	0.000389	0.00138	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Betamethasone—psoriasis	0.000389	0.00138	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Cyclosporine—psoriasis	0.000384	0.00136	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Acitretin—psoriasis	0.000383	0.00136	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000382	0.0141	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Fluocinolone Acetonide—psoriasis	0.000382	0.00135	CcSEcCtD
Bismuth Subsalicylate—Rash—Acitretin—psoriasis	0.00038	0.00135	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Acitretin—psoriasis	0.000379	0.00134	CcSEcCtD
Bismuth Subsalicylate—Rash—Fluocinolone Acetonide—psoriasis	0.000379	0.00134	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000378	0.00134	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Mycophenolic acid—psoriasis	0.000377	0.00134	CcSEcCtD
Bismuth Subsalicylate—Headache—Acitretin—psoriasis	0.000377	0.00134	CcSEcCtD
Bismuth Subsalicylate—Headache—Fluocinolone Acetonide—psoriasis	0.000376	0.00133	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Mycophenolate mofetil—psoriasis	0.000375	0.00133	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Hydroxyurea—psoriasis	0.000374	0.00132	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Methotrexate—psoriasis	0.000368	0.0013	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.000365	0.0135	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Acitretin—psoriasis	0.000358	0.00127	CcSEcCtD
Bismuth Subsalicylate—Erythema—Prednisolone—psoriasis	0.000357	0.00127	CcSEcCtD
Bismuth Subsalicylate—Nausea—Fluocinolone Acetonide—psoriasis	0.000357	0.00126	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Mycophenolic acid—psoriasis	0.000352	0.00125	CcSEcCtD
Bismuth Subsalicylate—Erythema—Hydrocortisone—psoriasis	0.000349	0.00124	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Mycophenolic acid—psoriasis	0.000349	0.00124	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000348	0.0129	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000345	0.0128	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Mycophenolic acid—psoriasis	0.000344	0.00122	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Dexamethasone—psoriasis	0.000341	0.00121	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Betamethasone—psoriasis	0.000341	0.00121	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Prednisone—psoriasis	0.000339	0.0012	CcSEcCtD
Bismuth Subsalicylate—Pain—Mycophenolic acid—psoriasis	0.000339	0.0012	CcSEcCtD
Bismuth Subsalicylate—Constipation—Mycophenolic acid—psoriasis	0.000339	0.0012	CcSEcCtD
Bismuth Subsalicylate—Erythema—Triamcinolone—psoriasis	0.000328	0.00116	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Mycophenolic acid—psoriasis	0.000326	0.00116	CcSEcCtD
Bismuth Subsalicylate—TF—Differentiation Pathway—IL6—psoriasis	0.000326	0.0121	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Hydroxyurea—psoriasis	0.000323	0.00115	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Cyclosporine—psoriasis	0.000323	0.00114	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Triamcinolone—psoriasis	0.000322	0.00114	CcSEcCtD
Bismuth Subsalicylate—Oedema—Cyclosporine—psoriasis	0.00032	0.00114	CcSEcCtD
Bismuth Subsalicylate—Infection—Cyclosporine—psoriasis	0.000318	0.00113	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Mycophenolate mofetil—psoriasis	0.000315	0.00112	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Mycophenolic acid—psoriasis	0.000313	0.00111	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet degranulation—VEGFA—psoriasis	0.000313	0.0116	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Hydroxyurea—psoriasis	0.000313	0.00111	CcSEcCtD
Bismuth Subsalicylate—Oedema—Mycophenolate mofetil—psoriasis	0.000312	0.00111	CcSEcCtD
Bismuth Subsalicylate—Asthma—Methotrexate—psoriasis	0.000311	0.0011	CcSEcCtD
Bismuth Subsalicylate—Infection—Mycophenolate mofetil—psoriasis	0.00031	0.0011	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Cyclosporine—psoriasis	0.000305	0.00108	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—ITGAL—psoriasis	0.000301	0.0111	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Hydroxyurea—psoriasis	0.000301	0.00107	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Methotrexate—psoriasis	0.000298	0.00106	CcSEcCtD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	0.000298	0.011	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Hydroxyurea—psoriasis	0.000298	0.00106	CcSEcCtD
Bismuth Subsalicylate—Erythema—Betamethasone—psoriasis	0.000298	0.00106	CcSEcCtD
Bismuth Subsalicylate—Erythema—Dexamethasone—psoriasis	0.000298	0.00106	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Mycophenolate mofetil—psoriasis	0.000298	0.00106	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Hydroxyurea—psoriasis	0.000298	0.00106	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Prednisone—psoriasis	0.000297	0.00105	CcSEcCtD
Bismuth Subsalicylate—Headache—Hydroxyurea—psoriasis	0.000296	0.00105	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000292	0.0108	CbGpPWpGaD
Bismuth Subsalicylate—Oedema—Prednisolone—psoriasis	0.000291	0.00103	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000291	0.0346	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000291	0.0346	CbGdCrCtD
Bismuth Subsalicylate—Somnolence—Cyclosporine—psoriasis	0.000285	0.00101	CcSEcCtD
Bismuth Subsalicylate—Oedema—Hydrocortisone—psoriasis	0.000285	0.00101	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000284	0.0338	CbGdCrCtD
Bismuth Subsalicylate—Infection—Hydrocortisone—psoriasis	0.000283	0.001	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Cyclosporine—psoriasis	0.000282	0.001	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000281	0.0104	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Hydroxyurea—psoriasis	0.000281	0.000995	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Mycophenolic acid—psoriasis	0.00028	0.000993	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Cyclosporine—psoriasis	0.000278	0.000987	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Mycophenolate mofetil—psoriasis	0.000278	0.000985	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Methotrexate—psoriasis	0.000278	0.000984	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000275	0.000975	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000274	0.0101	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Cyclosporine—psoriasis	0.000274	0.000971	CcSEcCtD
Bismuth Subsalicylate—Pain—Cyclosporine—psoriasis	0.000274	0.000971	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000272	0.000963	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Hydrocortisone—psoriasis	0.000271	0.000962	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mycophenolic acid—psoriasis	0.000271	0.00096	CcSEcCtD
Bismuth Subsalicylate—Oedema—Triamcinolone—psoriasis	0.000268	0.00095	CcSEcCtD
Bismuth Subsalicylate—Constipation—Mycophenolate mofetil—psoriasis	0.000267	0.000947	CcSEcCtD
Bismuth Subsalicylate—Pain—Mycophenolate mofetil—psoriasis	0.000267	0.000947	CcSEcCtD
Bismuth Subsalicylate—Infection—Triamcinolone—psoriasis	0.000266	0.000944	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Cyclosporine—psoriasis	0.000264	0.000936	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Mycophenolic acid—psoriasis	0.000262	0.000928	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Methotrexate—psoriasis	0.000262	0.000928	CcSEcCtD
Bismuth Subsalicylate—Erythema—Prednisone—psoriasis	0.00026	0.00092	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000257	0.000913	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000255	0.00945	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Cyclosporine—psoriasis	0.000254	0.000902	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Cyclosporine—psoriasis	0.000253	0.000898	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mycophenolic acid—psoriasis	0.000252	0.000892	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—CP—psoriasis	0.000252	0.00931	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Hydrocortisone—psoriasis	0.000251	0.000888	CcSEcCtD
Bismuth Subsalicylate—Rash—Mycophenolic acid—psoriasis	0.00025	0.000885	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mycophenolic acid—psoriasis	0.000249	0.000884	CcSEcCtD
Bismuth Subsalicylate—Pain—Prednisolone—psoriasis	0.000249	0.000884	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Methotrexate—psoriasis	0.000249	0.000883	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Mycophenolate mofetil—psoriasis	0.000248	0.00088	CcSEcCtD
Bismuth Subsalicylate—Headache—Mycophenolic acid—psoriasis	0.000248	0.000879	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Hydrocortisone—psoriasis	0.000247	0.000877	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000247	0.000876	CcSEcCtD
Bismuth Subsalicylate—Pain—Hydrocortisone—psoriasis	0.000243	0.000863	CcSEcCtD
Bismuth Subsalicylate—Oedema—Dexamethasone—psoriasis	0.000243	0.000862	CcSEcCtD
Bismuth Subsalicylate—Oedema—Betamethasone—psoriasis	0.000243	0.000862	CcSEcCtD
Bismuth Subsalicylate—Infection—Betamethasone—psoriasis	0.000242	0.000857	CcSEcCtD
Bismuth Subsalicylate—Infection—Dexamethasone—psoriasis	0.000242	0.000857	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.00024	0.00889	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Prednisolone—psoriasis	0.00024	0.000852	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—CARM1—psoriasis	0.00024	0.00888	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Triamcinolone—psoriasis	0.000236	0.000836	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000236	0.00872	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—psoriasis	0.000236	0.000835	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mycophenolic acid—psoriasis	0.000235	0.000834	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Hydrocortisone—psoriasis	0.000235	0.000832	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—psoriasis	0.000232	0.000824	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Betamethasone—psoriasis	0.000232	0.000822	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Dexamethasone—psoriasis	0.000232	0.000822	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Prednisolone—psoriasis	0.000232	0.000821	CcSEcCtD
Bismuth Subsalicylate—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000231	0.00857	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Triamcinolone—psoriasis	0.000229	0.000813	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Cyclosporine—psoriasis	0.000227	0.000803	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Hydrocortisone—psoriasis	0.000226	0.000802	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000226	0.00836	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Hydrocortisone—psoriasis	0.000225	0.000798	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000225	0.00832	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000223	0.00824	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Mycophenolate mofetil—psoriasis	0.000221	0.000784	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Triamcinolone—psoriasis	0.000221	0.000783	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Cyclosporine—psoriasis	0.000219	0.000777	CcSEcCtD
Bismuth Subsalicylate—Erythema—Methotrexate—psoriasis	0.000217	0.000769	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Dexamethasone—psoriasis	0.000214	0.000759	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Betamethasone—psoriasis	0.000214	0.000759	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000214	0.000758	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Triamcinolone—psoriasis	0.000213	0.000755	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—psoriasis	0.000212	0.000753	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Triamcinolone—psoriasis	0.000212	0.000751	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Cyclosporine—psoriasis	0.000212	0.000751	CcSEcCtD
Bismuth Subsalicylate—Oedema—Prednisone—psoriasis	0.000212	0.000751	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dexamethasone—psoriasis	0.000211	0.00075	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Betamethasone—psoriasis	0.000211	0.00075	CcSEcCtD
Bismuth Subsalicylate—Infection—Prednisone—psoriasis	0.00021	0.000746	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.00021	0.00777	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—JUN—psoriasis	0.00021	0.00777	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Betamethasone—psoriasis	0.000208	0.000737	CcSEcCtD
Bismuth Subsalicylate—Pain—Dexamethasone—psoriasis	0.000208	0.000737	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Mycophenolate mofetil—psoriasis	0.000207	0.000733	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Cyclosporine—psoriasis	0.000204	0.000722	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000202	0.00748	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Cyclosporine—psoriasis	0.000202	0.000716	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Prednisone—psoriasis	0.000202	0.000716	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Cyclosporine—psoriasis	0.000202	0.000715	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Hydrocortisone—psoriasis	0.000201	0.000714	CcSEcCtD
Bismuth Subsalicylate—Headache—Cyclosporine—psoriasis	0.000201	0.000711	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Dexamethasone—psoriasis	0.0002	0.000711	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Betamethasone—psoriasis	0.0002	0.000711	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mycophenolate mofetil—psoriasis	0.000199	0.000704	CcSEcCtD
Bismuth Subsalicylate—Rash—Mycophenolate mofetil—psoriasis	0.000197	0.000698	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mycophenolate mofetil—psoriasis	0.000197	0.000698	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000196	0.00726	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Mycophenolate mofetil—psoriasis	0.000196	0.000694	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Hydrocortisone—psoriasis	0.000195	0.00069	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000194	0.00717	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Betamethasone—psoriasis	0.000193	0.000685	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Dexamethasone—psoriasis	0.000193	0.000685	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Prednisolone—psoriasis	0.000193	0.000683	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Dexamethasone—psoriasis	0.000192	0.000682	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Betamethasone—psoriasis	0.000192	0.000682	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.000191	0.00706	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Cyclosporine—psoriasis	0.00019	0.000674	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Triamcinolone—psoriasis	0.00019	0.000672	CcSEcCtD
Bismuth Subsalicylate—ALB—Hemostasis—SERPINB8—psoriasis	0.000189	0.00699	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Hydrocortisone—psoriasis	0.000188	0.000667	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Prednisone—psoriasis	0.000186	0.000661	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mycophenolate mofetil—psoriasis	0.000186	0.000658	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Prednisone—psoriasis	0.000184	0.000653	CcSEcCtD
Bismuth Subsalicylate—Rash—Prednisolone—psoriasis	0.000184	0.000652	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Prednisolone—psoriasis	0.000184	0.000651	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000183	0.00679	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Prednisolone—psoriasis	0.000183	0.000647	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.000182	0.00672	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Prednisone—psoriasis	0.000181	0.000642	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Hydrocortisone—psoriasis	0.000181	0.000642	CcSEcCtD
Bismuth Subsalicylate—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	0.00018	0.00667	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Hydrocortisone—psoriasis	0.000179	0.000636	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Hydrocortisone—psoriasis	0.000179	0.000636	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Methotrexate—psoriasis	0.000178	0.000633	CcSEcCtD
Bismuth Subsalicylate—Headache—Hydrocortisone—psoriasis	0.000178	0.000632	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Triamcinolone—psoriasis	0.000177	0.000628	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000177	0.00655	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Methotrexate—psoriasis	0.000176	0.000623	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Prednisone—psoriasis	0.000175	0.000619	CcSEcCtD
Bismuth Subsalicylate—Nausea—Prednisolone—psoriasis	0.000173	0.000614	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Dexamethasone—psoriasis	0.000172	0.00061	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Betamethasone—psoriasis	0.000172	0.00061	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Triamcinolone—psoriasis	0.00017	0.000604	CcSEcCtD
Bismuth Subsalicylate—Nausea—Hydrocortisone—psoriasis	0.000169	0.000599	CcSEcCtD
Bismuth Subsalicylate—Rash—Triamcinolone—psoriasis	0.000169	0.000599	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Triamcinolone—psoriasis	0.000169	0.000599	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Methotrexate—psoriasis	0.000169	0.000598	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Prednisone—psoriasis	0.000168	0.000597	CcSEcCtD
Bismuth Subsalicylate—Headache—Triamcinolone—psoriasis	0.000168	0.000595	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Prednisone—psoriasis	0.000167	0.000594	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Betamethasone—psoriasis	0.000166	0.00059	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Dexamethasone—psoriasis	0.000166	0.00059	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.000166	0.00613	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Dexamethasone—psoriasis	0.000161	0.00057	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Betamethasone—psoriasis	0.000161	0.00057	CcSEcCtD
Bismuth Subsalicylate—Nausea—Triamcinolone—psoriasis	0.000159	0.000564	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—CAT—psoriasis	0.000159	0.00587	CbGpPWpGaD
Bismuth Subsalicylate—Somnolence—Methotrexate—psoriasis	0.000157	0.000558	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—TNF—psoriasis	0.000157	0.00582	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000156	0.00578	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—psoriasis	0.000156	0.000552	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000156	0.00576	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	0.000156	0.00576	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—CRP—psoriasis	0.000155	0.00573	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Dexamethasone—psoriasis	0.000155	0.000548	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Betamethasone—psoriasis	0.000155	0.000548	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	0.000154	0.0057	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—psoriasis	0.000154	0.000546	CcSEcCtD
Bismuth Subsalicylate—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	0.000154	0.00569	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Betamethasone—psoriasis	0.000153	0.000544	CcSEcCtD
Bismuth Subsalicylate—Rash—Dexamethasone—psoriasis	0.000153	0.000544	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Dexamethasone—psoriasis	0.000153	0.000543	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Betamethasone—psoriasis	0.000153	0.000543	CcSEcCtD
Bismuth Subsalicylate—Headache—Dexamethasone—psoriasis	0.000152	0.00054	CcSEcCtD
Bismuth Subsalicylate—Headache—Betamethasone—psoriasis	0.000152	0.00054	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—APOE—psoriasis	0.000151	0.0056	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Methotrexate—psoriasis	0.000151	0.000537	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Prednisone—psoriasis	0.00015	0.000531	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—psoriasis	0.000146	0.000517	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL4—psoriasis	0.000146	0.00539	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Prednisone—psoriasis	0.000145	0.000514	CcSEcCtD
Bismuth Subsalicylate—Nausea—Betamethasone—psoriasis	0.000144	0.000512	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dexamethasone—psoriasis	0.000144	0.000512	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	0.000143	0.0053	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000142	0.00526	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Methotrexate—psoriasis	0.000141	0.000499	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Prednisone—psoriasis	0.00014	0.000497	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—psoriasis	0.00014	0.000496	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000139	0.00514	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000136	0.00503	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Prednisone—psoriasis	0.000135	0.000477	CcSEcCtD
Bismuth Subsalicylate—Rash—Prednisone—psoriasis	0.000134	0.000473	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Prednisone—psoriasis	0.000133	0.000473	CcSEcCtD
Bismuth Subsalicylate—Headache—Prednisone—psoriasis	0.000133	0.00047	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—IL6—psoriasis	0.000127	0.00469	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000126	0.00468	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—CAT—psoriasis	0.000126	0.00466	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—CRP—psoriasis	0.000126	0.00466	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Prednisone—psoriasis	0.000126	0.000446	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Methotrexate—psoriasis	0.000125	0.000444	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	0.000124	0.00457	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NOS2—psoriasis	0.000124	0.00457	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—psoriasis	0.000121	0.000429	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000121	0.00447	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000117	0.00435	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Methotrexate—psoriasis	0.000117	0.000415	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—ICAM1—psoriasis	0.000116	0.00428	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	0.000114	0.0042	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL4—psoriasis	0.000113	0.00419	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Methotrexate—psoriasis	0.000113	0.000399	CcSEcCtD
Bismuth Subsalicylate—Rash—Methotrexate—psoriasis	0.000112	0.000396	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—psoriasis	0.000112	0.000395	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—psoriasis	0.000111	0.000393	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.00011	0.00406	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	0.000109	0.00403	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	0.000108	0.004	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Methotrexate—psoriasis	0.000105	0.000373	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000103	0.00382	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—CRP—psoriasis	0.0001	0.0037	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—LEP—psoriasis	9.57e-05	0.00354	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	9.4e-05	0.00348	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	9.19e-05	0.0034	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	9.06e-05	0.00335	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—CP—psoriasis	9.02e-05	0.00334	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	9e-05	0.00333	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	8.98e-05	0.00332	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—NOS2—psoriasis	8.91e-05	0.0033	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—IFNG—psoriasis	8.8e-05	0.00326	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	8.8e-05	0.00325	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CD4—psoriasis	8.67e-05	0.00321	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	8.65e-05	0.0032	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NDUFA5—psoriasis	7.68e-05	0.00284	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—NFKB1—psoriasis	7.33e-05	0.00271	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7.22e-05	0.00267	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	7.19e-05	0.00266	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.16e-05	0.00265	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—psoriasis	7.15e-05	0.00265	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	7.05e-05	0.00261	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—TNF—psoriasis	7e-05	0.00259	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—IFNG—psoriasis	6.99e-05	0.00259	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IFNG—psoriasis	6.84e-05	0.00253	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP2S1—psoriasis	6.53e-05	0.00242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	6.36e-05	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NDUFA5—psoriasis	6.1e-05	0.00226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.06e-05	0.00224	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	5.82e-05	0.00215	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—psoriasis	5.7e-05	0.00211	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TNF—psoriasis	5.7e-05	0.00211	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	5.69e-05	0.0021	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.69e-05	0.0021	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—IL6—psoriasis	5.65e-05	0.00209	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	5.6e-05	0.00207	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ITGAL—psoriasis	5.48e-05	0.00203	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	5.43e-05	0.00201	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—psoriasis	5.41e-05	0.002	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP2S1—psoriasis	5.19e-05	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—psoriasis	5.02e-05	0.00186	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NDUFA5—psoriasis	4.93e-05	0.00183	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.6e-05	0.0017	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL6—psoriasis	4.6e-05	0.0017	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CP—psoriasis	4.59e-05	0.0017	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TNF—psoriasis	4.53e-05	0.00168	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	4.52e-05	0.00167	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TNF—psoriasis	4.42e-05	0.00164	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	4.37e-05	0.00162	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP2S1—psoriasis	4.19e-05	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.02e-05	0.00149	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—psoriasis	3.9e-05	0.00144	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.87e-05	0.00143	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—IL6—psoriasis	3.65e-05	0.00135	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL6—psoriasis	3.57e-05	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.51e-05	0.0013	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.42e-05	0.00127	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CARM1—psoriasis	3.19e-05	0.00118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.01e-05	0.00111	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.98e-05	0.0011	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.72e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.65e-05	0.000982	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CARM1—psoriasis	2.53e-05	0.000937	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.53e-05	0.000936	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.37e-05	0.000876	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NOS2—psoriasis	2.25e-05	0.000833	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.2e-05	0.000814	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CARM1—psoriasis	2.05e-05	0.000758	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CAT—psoriasis	1.96e-05	0.000726	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.91e-05	0.000709	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CAT—psoriasis	1.56e-05	0.000576	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HLA-A—psoriasis	1.55e-05	0.000573	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—APOE—psoriasis	1.52e-05	0.000564	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APOE—psoriasis	1.45e-05	0.000535	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOS2—psoriasis	1.35e-05	0.000498	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—psoriasis	1.33e-05	0.000491	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—psoriasis	1.3e-05	0.000482	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CAT—psoriasis	1.26e-05	0.000466	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—APOE—psoriasis	1.21e-05	0.000448	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TYK2—psoriasis	1.1e-05	0.000408	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—psoriasis	1.05e-05	0.00039	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD4—psoriasis	9.97e-06	0.000369	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—psoriasis	9.85e-06	0.000364	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—APOE—psoriasis	9.79e-06	0.000362	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—psoriasis	8.53e-06	0.000316	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT3—psoriasis	7.72e-06	0.000286	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6—psoriasis	5.39e-06	0.0002	CbGpPWpGaD
